SERPINE1 and head and neck squamous cell carcinoma: Theoretically, a PAI-1-inhibitor could have a therapeutic potential to reduce cardiovascular morbidity for patients receiving radiotherapy, as well as affecting features of prognostic importance for patients with HNSCC.